Insights

Capstone Turbine Represents An Attractive Entry Point For LT Holders, Says Roth Capital

In a research note issued this morning, Roth Capital reiterated coverage with a “Buy” rating on Capstone Turbine Corp. (CPST) and a price target of $1.

CTI BioPharma Reiterated With A Buy At H.C. Wainwright

In a research note issued this morning, H.C.

We Continue To Remain Supportive Of Vertex Shares, Says Janney Analyst

In a research note released this morning, Janney Montgomery Scott reiterated coverage on Vertex Pharmaceuticals (VRTX) with an Outperform rating and $90 fair value estimate. A data …

William Blair Reiterates Outperform On Encore Capital

In a research note released today, William Blair reiterated coverage on Encore Capital Group, Inc (ECPG) with an Outperform rating. Blair analyst Robert Napoli has increased confidence in Encore’s long-term growth …

Wedbush Reiterates An Outperform Rating On Smith & Wesson; Expects Market Share Gains

In a research note issued today, Wedbush reiterated coverage with a “Buy” rating on Smith & Wesson (SWHC), and a price target of $20.00 a share.

We Like Ariad’s Story But See Limited Newsflow, Says UBS’ Andrew Peters

Ariad Pharmaceuticals (ARIA) had its price target reduced by UBS from $7.50 to $7.

TG Therapeutics Is Poised For Upside, Says Roth Capital Analyst

In a research note released today, Roth Capital reiterated coverage on TG Therapeutics, Inc. (TGTX) with a Buy rating and a price target of $15.

Regeneron Has Solid Growth Prospects, Says Roth Capital Analyst

In a research note released this morning, Roth Capital reiterated coverage on Regeneron Pharmaceuticals (REGN) with a Buy rating and a price target of $382.00, following the announcement that …

Palatin Technologies Reiterated With A Buy At Roth Capital

In a research note issued this morning, Roth Capital reiterated coverage with a “Buy” rating on Palatin Technologies, Inc. (PTN) and a price target of $6.

Roth Capital Reiterates Buy Rating for Celator Pharmaceuticals

In a research note released this morning, Roth Capital reiterated coverage on Celator Pharmaceuticals, Inc (CPXX) with an Outperform rating and a price target of $15.00, which is based …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts